School of Applied Psychology, University College Cork, Cork, Ireland.
Cork University Hospital, University College Cork, Cork, Ireland.
Allergy. 2018 Mar;73(3):560-568. doi: 10.1111/all.13330. Epub 2017 Nov 13.
We previously reported that probiotic and peanut oral immunotherapy (PPOIT) was effective at inducing sustained unresponsiveness compared with placebo in a double-blind, placebo-controlled randomized trial. This study evaluated the impact of PPOIT on health-related quality of life (HRQL).
Fifty-one participants (PPOIT 24; placebo 27) from the PPOIT trial completed Food Allergy Quality of Life Questionnaire (FAQLQ-PF) and Food Allergy Independent Measure (FAIM) at pre-treatment, end-of-treatment and 3 months after end-of-treatment. A total of 42 participants (20 PPOIT; 22 placebo) completed measures at 12 months post-treatment. Changes over time in PPOIT and placebo groups were examined by repeated-measures analysis of variance and paired t tests.
Probiotic and peanut oral immunotherapy was associated with significant improvement in FAQLQ-PF (F = 3.63, P = .02), with mean difference 0.8 at 3 months post-treatment (P = .05) and 1.3 at 12 months post-treatment (P = .005), exceeding the 0.5 minimal clinically important difference for FAQLQ-PF. For FAIM, mean difference was 0.5 (P = .03) at 3 months and 0.4 (P = .04) at 12 months post-treatment. In placebo group, post-treatment FAQLQ and FAIM remained unchanged from pretreatment. Improvement in FAQLQ-PF and FAIM scores related specifically to acquisition of sustained unresponsiveness rather than to receiving PPOIT treatment or participation in the trial.
Probiotic and peanut oral immunotherapy has a sustained beneficial effect on psychosocial impact of food allergy at 3 and 12 months after end-of-treatment. Treatment was not associated with reduced HRQL relative to baseline in either PPOIT or placebo groups, indicating that PPOIT was well tolerated and psychological well-being was not negatively impacted. Improved HRQL was specifically associated with acquisition of sustained unresponsiveness.
我们之前报道过，与安慰剂相比，益生菌和花生口服免疫疗法（PPOIT）在一项双盲、安慰剂对照的随机试验中能更有效地诱导持续无反应。本研究评估了 PPOIT 对健康相关生活质量（HRQL）的影响。
来自 PPOIT 试验的 51 名参与者（PPOIT 24 名；安慰剂 27 名）在治疗前、治疗结束时和治疗结束后 3 个月完成了食物过敏生活质量问卷（FAQLQ-PF）和食物过敏独立测量（FAIM）。共有 42 名参与者（PPOIT 20 名；安慰剂 22 名）在治疗后 12 个月完成了这些测量。通过重复测量方差分析和配对 t 检验来检查 PPOIT 和安慰剂组随时间的变化。
益生菌和花生口服免疫疗法与 FAQLQ-PF 的显著改善相关（F=3.63，P=0.02），治疗后 3 个月的平均差值为 0.8（P=0.05），治疗后 12 个月的平均差值为 1.3（P=0.005），超过了 FAQLQ-PF 的 0.5 最小临床重要差异。对于 FAIM，治疗后 3 个月的平均差值为 0.5（P=0.03），治疗后 12 个月的平均差值为 0.4（P=0.04）。在安慰剂组中，治疗后 FAQLQ 和 FAIM 与治疗前相比没有变化。FAQLQ-PF 和 FAIM 评分的改善与持续无反应的获得有关，而不是与接受 PPOIT 治疗或参与试验有关。
益生菌和花生口服免疫疗法在治疗结束后 3 个月和 12 个月对食物过敏的心理社会影响有持续的有益作用。在 PPOIT 组或安慰剂组中，治疗均未导致 HRQL 相对于基线下降，这表明 PPOIT 耐受性良好，心理健康未受到负面影响。HRQL 的改善与持续无反应的获得有关。
